CooperCompanies Announces MiSight® Approval in China
SAN RAMON, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), today announced that the Chinese National Medical Products...
Month: August 2021
Last Patient Last Visit Completed in Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for COVID-19; Trial Database Undergoing Review in Preparation for Database Lock
WAKEFIELD, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided...
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Investigational Hair Loss Therapeutic, OLX104C
SUWON, Republic of Korea, Aug. 12, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi...
Progyny, Inc. Offers Paid Pregnancy Loss Leave to its Employees
Fertility Benefits Company Enhances Bereavement Leave Policy to Explicitly Recognize the Physical, Emotional and Mental Health Impact of Pregnancy LossNew...
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
BERLIN, Aug. 12, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (Nasdaq: ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of...
Pure Extracts Ships Initial Vape Cart Order to BC Liquor Distribution Branch
VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure...
Nanox to Host Business Update Video Presentation
Company to host webcast on Monday, August 16th at 8:30 am ETNEVE ILAN, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) --...
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)
ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma PatientsPhase 1 Data...
MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs
Promotion Recognizes Skilled Leadership and Contributions to MIMEDX’s Continued Growth MARIETTA, Ga., Aug. 12, 2021 (GLOBE NEWSWIRE) -- MiMedx Group,...
ABVC BioPharma Reports Second Quarter 2021 Results
Clinical Trials Continue Despite COVID-19 Restrictions Fremont, CA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc., a clinical...
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to...
Revive Confirms No Material Undisclosed Information
TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (Frankfurt:31R), a...
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 Results
Interim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter...
Fluo Labs Announces Partnership With a Leading Global Life Sciences Company
New Partnership will help Fluo Labs Bring to Market its Medical Device, Designed to Improve Hay Fever Symptoms via Light...
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
–1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLA–SHANGHAI, China, and REDWOOD CITY, Calif.,...
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma
1st line nasopharyngeal indication and 2nd/3rd line indications to be concurrently submitted 3Q 2021 in the toripalimab BLASHANGHAI, China and...
Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. Eastern TimeSAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:...
Origin Therapeutics Closes $6.5 Million Private Placement to Fund New Investments in Psychedelics
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES VANCOUVER, British Columbia, Aug. 12, 2021...
Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates
Camsirubicin Phase 1b Clinical Trial Anticipated to Start in the U.S. in Q4 2021Validive® Phase 2b/3 VOICE Trial on Track...
Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates
Continued Company investment across our iPSC platforms, programs, and manufacturingLead program, CNTY-101, remains on track for IND filing in mid-2022Recent...
